Last reviewed · How we verify

AO GENERIUM — Portfolio Competitive Intelligence Brief

AO GENERIUM pipeline: 3 marketed, 0 filed, 13 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 13 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Actemra® Actemra® marketed
Ilaris® Ilaris® marketed IL-1β inhibitor (monoclonal antibody) IL-1β (Interleukin-1 beta) Immunology / Rheumatology / Rare Inflammatory Diseases
Pulmozyme® Pulmozyme® marketed Recombinant enzyme Extracellular DNA Pulmonology / Respiratory
Tigerase® and best available care Tigerase® and best available care phase 3 SGLT2 inhibitor SGLT2 Diabetes
GNR-069 GNR-069 phase 3 SGLT2 inhibitor SGLT2 Diabetes
GNR-060 GNR-060 phase 3 SGLT2 inhibitor SGLT2 Diabetes
GNR-067 GNR-067 phase 3 SGLT2 inhibitor SGLT2 Diabetes
Revelise (GENERIUM, Russia) Revelise (GENERIUM, Russia) phase 3 Erythropoietin-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology/Oncology
Genolar® + Symbicort® Genolar® + Symbicort® phase 3 Inhaled corticosteroid/long-acting beta-2 agonist combination Beta-2 adrenergic receptor; glucocorticoid receptor Respiratory/Pulmonology
GNR-068 GNR-068 phase 3 SGLT2 inhibitor SGLT2 Diabetes
Xolair® + Symbicort® Xolair® + Symbicort® phase 3 Anti-IgE antibody and corticosteroid/long-acting beta2-adrenergic receptor agonist combination IgE receptor Asthma
Tigerase® Tigerase® phase 3 SGLT2 inhibitor SGLT2 Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 3 shared drug classes
  2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
  3. AstraZeneca · 2 shared drug classes
  4. Hoffmann-La Roche · 2 shared drug classes
  5. Promius Pharma, LLC · 2 shared drug classes
  6. Takeda · 2 shared drug classes
  7. Nobelpharma · 2 shared drug classes
  8. University Hospital, Strasbourg, France · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for AO GENERIUM:

Cite this brief

Drug Landscape (2026). AO GENERIUM — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ao-generium. Accessed 2026-05-13.

Related